A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE

Melissa Hodeib; Tasha Serna-Gallegos; Krishnansu S Tewari

doi:10.2217/fon.15.266

A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE

Future Oncol. 2015;11(23):3113-31. doi: 10.2217/fon.15.266. Epub 2015 Nov 24.

Authors

Melissa Hodeib¹, Tasha Serna-Gallegos¹, Krishnansu S Tewari¹

Affiliation

¹ Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine-Medical Center, Orange, CA, USA.

PMID: 26597460
DOI: 10.2217/fon.15.266

Abstract

Although breast and ovarian cancer have notable distinctions, there may exist parallel pathways that can be exploited for therapeutic gain. For example, the therapeutic arena in breast cancer has benefited greatly from available endocrine therapies as well as novel drugs designed to target the HER2 receptor, including trastuzumab, lapatinib, T-DM1 and pertuzumab. CLEOPATRA, a Phase III randomized clinical trial studying pertuzumab in women with HER2-amplified metastatic breast cancer, was practice-changing in 2014. Its counterpart, the Phase III randomized PENELOPE trial, was activated following promising Phase II data and studied pertuzumab in an enriched ovarian cancer patient population with low HER3 mRNA. This review will trace the development of anti-HER2 therapies in breast and ovarian cancer.

Keywords: CLEOPATRA; HER2/neu; PENELOPE; T-DM1; breast cancer; lapatinib; ovarian cancer; pertuzumab; trastuzumab.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / mortality
Breast Neoplasms / pathology
Carcinoma, Ovarian Epithelial
Clinical Trials, Phase III as Topic
Drug Discovery
Female
Gene Expression Regulation, Neoplastic / drug effects
Humans
Molecular Targeted Therapy
Neoplasms, Glandular and Epithelial / drug therapy
Neoplasms, Glandular and Epithelial / metabolism
Neoplasms, Glandular and Epithelial / pathology
Oncogene Proteins / genetics
Oncogene Proteins / metabolism
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / genetics
Ovarian Neoplasms / metabolism
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Randomized Controlled Trials as Topic
Receptor, ErbB-2 / antagonists & inhibitors*
Receptor, ErbB-2 / genetics
Treatment Outcome

Substances

Antineoplastic Agents
Oncogene Proteins
Receptor, ErbB-2